

Press release



U-Protein Express B.V. announces license agreement with ArGEN-X B.V.b.a..

Utrecht, The Netherlands, May 29th 2010 – U-Protein Express B.V., a dedicated service provider in the field of biotechnology based in the Netherlands, announces that it has closed its first non-exclusive license agreement with ArGEN-X B.V.b.a. for their proprietary r-PEx transient HEK293-based expression platform. ArGEN-X will use the r-PEx technology for their in-house production of recombinant antibodies.

About the r-PEx technology. U-Protein Express has developed the r-PEx technology for transient recombinant protein production in HEK293 cells. In only 4 – 6 weeks hundreds of milligram recombinant protein can be obtained. The technology is well established for secreted as well as intra-cellular mammalian proteins. Novel specialized expression vectors have been developed for the transient production of humanized recombinant antibodies.

About U-Protein Express. U-Protein Express is a dedicated contract research organization and offers various services. Fully post translational modified mammalian proteins can be produced via the r-PEx technology. In addition, *E. coli* and *P. pastoris* expression platforms are available for the production of more simple proteins. Produced recombinant proteins are purified in house by state-of-the-art purification technology. Main customers are academia, biotech- and pharma companies.

For more information on U-Protein Express B.V. or on the r-PEx technology please contact Dr. Martin Hessing, C.E.O. at M.Hessing@U-ProteinExpress.com.